{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T05:16:57Z","timestamp":1774070217547,"version":"3.50.1"},"reference-count":145,"publisher":"European Respiratory Society (ERS)","issue":"162","license":[{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2021,2,18]]},"published-print":{"date-parts":[[2021,12,31]]},"abstract":"<jats:p>The advent of immune checkpoint inhibitors (ICIs) has rapidly transformed the treatment paradigm for multiple cancer types, including thoracic malignancies. In advanced non-small cell lung cancer (NSCLC), ICIs have shifted treatment paradigm and improved overall survival reaching almost one-third of patients alive at 5\u2005years. ICIs therapies have also modified the therapeutic strategy in first-line setting in metastatic small-cell lung cancer (SCLC) patients as well as in malignant pleural mesothelioma (MPM) improving the overall survival compared with standard treatment. This phenomenon is of huge relevance as both SCLC and MPM were considered orphan diseases without any significant improvement in the therapeutic strategy in the first-line setting during the last 15\u2005years. In this review, we aim to review the efficacy of ICI in thoracic malignancies either in monotherapy or in combination, according to predictive biomarkers, and to the US Food and Drug Administration and the European Medicines Agency approvals of treatment strategies. We address the efficacy of these agents, especially in NSCLC according to PD-L1 expression and histologic subtype.<\/jats:p>","DOI":"10.1183\/16000617.0387-2020","type":"journal-article","created":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T08:05:52Z","timestamp":1633507552000},"page":"200387","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["The efficacy of immune checkpoint inhibitors in thoracic malignancies"],"prefix":"10.1183","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9462-875X","authenticated-orcid":false,"given":"Jordi","family":"Remon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Facchinetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2021,10,5]]},"reference":[{"key":"2024102403573011000_30.162.200387.1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.0412"},{"key":"2024102403573011000_30.162.200387.2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00934"},{"key":"2024102403573011000_30.162.200387.3","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1200\/JCO.19.02446","article-title":"Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1\u2013Positive, Advanced Non\u2013Small-Cell Lung Cancer in the KEYNOTE-010 Study","volume":"38","author":"Herbst","year":"2020","journal-title":"J Clin Oncol"},{"key":"2024102403573011000_30.162.200387.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"2024102403573011000_30.162.200387.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6"},{"issue":"Suppl. 15","key":"2024102403573011000_30.162.200387.6","doi-asserted-by":"crossref","first-page":"9002","DOI":"10.1200\/JCO.2020.38.15_suppl.9002","article-title":"Durvalumab\u00b1tremelimumab+platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study","volume":"38","author":"Paz-Ares","year":"2020","journal-title":"J Clin Oncol"},{"key":"2024102403573011000_30.162.200387.7","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"2024102403573011000_30.162.200387.8","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jtho.2020.03.006","article-title":"Immune checkpoint inhibitors in thoracic malignancies: review of the existing evidence by an IASLC expert panel and recommendations","volume":"15","author":"Remon","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2024102403573011000_30.162.200387.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30407-3"},{"key":"2024102403573011000_30.162.200387.10","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.1016\/j.jtho.2019.08.486","article-title":"Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017\/057: Nivolumab","volume":"14","author":"Gettinger","year":"2019","journal-title":"J Thoracic Oncol"},{"key":"2024102403573011000_30.162.200387.11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz288"},{"key":"2024102403573011000_30.162.200387.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.05.013"},{"key":"2024102403573011000_30.162.200387.13","doi-asserted-by":"publisher","DOI":"10.1038\/nature14011"},{"key":"2024102403573011000_30.162.200387.14","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jtho.2020.04.026","article-title":"Programmed death-ligand 1 heterogeneity and its impact on benefit from immune checkpoint inhibitors in NSCLC","volume":"15","author":"Hong","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2024102403573011000_30.162.200387.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"2024102403573011000_30.162.200387.16","doi-asserted-by":"crossref","first-page":"i38","DOI":"10.1093\/annonc\/mdz063","article-title":"Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1\u2013positive locally advanced\/metastatic NSCLC","volume":"30","author":"Mok","year":"2019","journal-title":"Ann Oncol"},{"key":"2024102403573011000_30.162.200387.17","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"key":"2024102403573011000_30.162.200387.18","doi-asserted-by":"crossref","first-page":"S1182","DOI":"10.1016\/j.annonc.2020.08.2285","article-title":"EMPOWER-Lung 1: Phase III first-line (1\u2005L) cemiplimab monotherapy","volume":"31","author":"Sezer","year":"2020","journal-title":"Ann Oncol"},{"key":"2024102403573011000_30.162.200387.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.9500"},{"key":"2024102403573011000_30.162.200387.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910231"},{"issue":"Suppl. 15","key":"2024102403573011000_30.162.200387.21","doi-asserted-by":"crossref","first-page":"9582","DOI":"10.1200\/JCO.2020.38.15_suppl.9582","article-title":"Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC)","volume":"38","author":"Rodriguez-Abreu","year":"2020","journal-title":"J Clin Oncol"},{"key":"2024102403573011000_30.162.200387.22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30167-6"},{"key":"2024102403573011000_30.162.200387.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948"},{"issue":"Suppl. 15","key":"2024102403573011000_30.162.200387.24","doi-asserted-by":"crossref","first-page":"9002","DOI":"10.1200\/JCO.2018.36.15_suppl.9002","article-title":"Overall survival (OS) analysis of IMpower150, a randomised Ph 3 study of atezolizumab (atezo)+chemotherapy (chemo)\u00b1bevacizumab (bev)","volume":"36","author":"Socinski","year":"2018","journal-title":"J Clin Oncol"},{"key":"2024102403573011000_30.162.200387.25","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.jtho.2020.07.014","article-title":"Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer: a randomised, double-blind, phase 3 study (ORIENT-11)","volume":"15","author":"Yang","year":"2020","journal-title":"J Thoracic Oncol"},{"key":"2024102403573011000_30.162.200387.26","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"A randomised, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous non-small-cell lung cancer: protocol-specified final analysis of KEYNOTE-407","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J Thoracic Oncol"},{"key":"2024102403573011000_30.162.200387.27","doi-asserted-by":"crossref","first-page":"S1186","DOI":"10.1016\/j.annonc.2020.08.2289","article-title":"ORIENT-12: Sintilimab plus gemcitabine and platinum (GP) as first-line (1\u2005L) treatment for locally advanced or metastatic squamous non-small-cell lung cancer (sqNSCLC)","volume":"31","author":"Zhou","year":"2020","journal-title":"Ann Oncol"},{"key":"2024102403573011000_30.162.200387.28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.9501"},{"key":"2024102403573011000_30.162.200387.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613493"},{"key":"2024102403573011000_30.162.200387.30","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/annonc\/mdy424.066","article-title":"IMpower132: efficacy of atezolizumab (atezo)+carboplatin (carbo)\/cisplatin (cis)+pemetrexed (pem) as 1\u2005L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC)","volume":"29:","author":"Barlesi","year":"2018","journal-title":"Ann Oncol"},{"key":"2024102403573011000_30.162.200387.31","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jtho.2020.03.028","article-title":"Atezolizumab in combination with carboplatin and Nab-Paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomised phase III trial","volume":"15","author":"Jotte","year":"2020","journal-title":"J Thoracic Oncol"},{"key":"2024102403573011000_30.162.200387.32","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaoncol.2020.0237","article-title":"Durvalumab with or without tremelimumab","volume":"6","author":"Rizvi","year":"2020","journal-title":"JAMA Oncol"},{"key":"2024102403573011000_30.162.200387.33","doi-asserted-by":"crossref","first-page":"S1181","DOI":"10.1016\/j.annonc.2020.08.2284","article-title":"KEYNOTE-024 5-year OS update: First-line (1\u2005L) pembrolizumab (pembro)","volume":"31","author":"Brahmer","year":"2020","journal-title":"Ann Oncol"},{"key":"2024102403573011000_30.162.200387.34","doi-asserted-by":"crossref","unstructured":"Spigel D , de Marinis F , Giaccone G , et al. IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) versus platinum-based chemotherapy (chemo) as first-line (1\u2005L) treatment (tx) in PD-L1\u2013selected NSCLC. Ann Oncol 2019; 30: Suppl. 5, v915. doi:10.1093\/annonc\/mdz293","DOI":"10.1093\/annonc\/mdz293"},{"key":"2024102403573011000_30.162.200387.35","doi-asserted-by":"crossref","first-page":"S243","DOI":"10.1016\/j.jtho.2019.08.483","article-title":"KEYNOTE-024 3-Year survival update: Pembrolizumab","volume":"14","author":"Reck","year":"2019","journal-title":"J Thoracic Oncol"},{"key":"2024102403573011000_30.162.200387.36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7"},{"key":"2024102403573011000_30.162.200387.37","doi-asserted-by":"crossref","first-page":"S826","DOI":"10.1016\/j.annonc.2020.08.1592","article-title":"Hyperprogressive disease (HPD) upon first-line PD-1\/PD-L1 inhibitors (ICI) as single agent or in combination with platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients (pts)","volume":"31","author":"Ferrara","year":"2020","journal-title":"Ann Oncol"},{"key":"2024102403573011000_30.162.200387.38","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS18-CT043"},{"key":"2024102403573011000_30.162.200387.39","doi-asserted-by":"crossref","first-page":"xi67","DOI":"10.1093\/annonc\/mdz453.004","article-title":"Nivolumab (NIVO)+platinum-doublet chemotherapy (chemo)","volume":"30","author":"Paz-Ares","year":"2019","journal-title":"Ann Oncol"},{"key":"2024102403573011000_30.162.200387.40","doi-asserted-by":"crossref","first-page":"9502","DOI":"10.1200\/JCO.2020.38.15_suppl.9502","article-title":"CCTG BR.34: a randomised trial of durvalumab and tremelimumab \u00b1 platinum-based chemotherapy in patients with metastatic (Stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC)","volume":"38","author":"Leighl","year":"2020","journal-title":"J Clin Oncol"},{"key":"2024102403573011000_30.162.200387.41","doi-asserted-by":"crossref","unstructured":"Rodriguez-Abreu D , Powell SF , Hochmair M , et al. Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 2020; 38; Suppl 15., 9582\u20139582. doi:10.1200\/JCO.2020.38.15_suppl.9582","DOI":"10.1200\/JCO.2020.38.15_suppl.9582"},{"key":"2024102403573011000_30.162.200387.42","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1634\/theoncologist.2019-0814","article-title":"Lack of association between radiographic tumor burden and efficacy of immune checkpoint inhibitors in advanced lung cancer","volume":"25","author":"Popat","year":"2020","journal-title":"Oncologist"},{"key":"2024102403573011000_30.162.200387.43","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000500885","article-title":"Immuno-oncological treatment and tumor mass in non-small cell lung cancer: case-control analysis of overall survival in routine clinical practice","volume":"97","author":"Faehling","year":"2019","journal-title":"Oncology"},{"key":"2024102403573011000_30.162.200387.44","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00259-019-04615-x","article-title":"Baseline metabolic tumor burden on FDG PET\/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors","volume":"47","author":"Seban","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2024102403573011000_30.162.200387.45","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1053\/j.seminoncol.2019.10.002","article-title":"Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors","volume":"46","author":"Hopkins","year":"2019","journal-title":"Semin Oncol"},{"key":"2024102403573011000_30.162.200387.46","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3389\/fonc.2019.00264","article-title":"Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung cancer: a systematic review and literature-based meta-analysis","volume":"9","author":"Addeo","year":"2019","journal-title":"Front Oncol"},{"key":"2024102403573011000_30.162.200387.47","doi-asserted-by":"crossref","first-page":"S1124","DOI":"10.1016\/j.jtho.2019.09.016","article-title":"Pembrolizumab plus chemotherapy for advanced NSCLC without Tumor PD-L1 expression: pooled analysis of KN021G, KN189 and KN407","volume":"14","author":"Borghaei","year":"2019","journal-title":"J Thoracic Oncol"},{"key":"2024102403573011000_30.162.200387.48","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2217\/fon-2020-0171","article-title":"Using biomarkers to determine optimal combinations with immunotherapy (biomarker discovery perspective)","volume":"16","author":"Teixido","year":"2020","journal-title":"Future Oncol"},{"key":"2024102403573011000_30.162.200387.49","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.annonc.2020.04.004","article-title":"HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients","volume":"31","author":"Shim","year":"2020","journal-title":"Ann Oncol"},{"key":"2024102403573011000_30.162.200387.50","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1348"},{"key":"2024102403573011000_30.162.200387.51","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.18.01042","article-title":"First-line Nivolumab plus Ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers","volume":"37","author":"Ready","year":"2019","journal-title":"J Clin Oncol"},{"key":"2024102403573011000_30.162.200387.52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801946"},{"key":"2024102403573011000_30.162.200387.53","doi-asserted-by":"crossref","first-page":"v916","DOI":"10.1093\/annonc\/mdz394.077","article-title":"Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials","volume":"30","author":"Herbst","year":"2019","journal-title":"Ann Oncol"},{"key":"2024102403573011000_30.162.200387.54","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1016\/j.jtho.2019.08.427","article-title":"Evaluation of TMB in KEYNOTE-189: pembrolizumab plus chemotherapy","volume":"14","author":"Garassino","year":"2019","journal-title":"J Thoracic Oncol"},{"key":"2024102403573011000_30.162.200387.55","doi-asserted-by":"crossref","first-page":"v477","DOI":"10.1093\/annonc\/mdz253.018","article-title":"Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158","volume":"30","author":"Marabelle","year":"2019","journal-title":"Ann Oncol"},{"key":"2024102403573011000_30.162.200387.56","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2018-5706"},{"key":"2024102403573011000_30.162.200387.57","doi-asserted-by":"crossref","unstructured":"Socinski M , Velcheti V , Mekhail T , et al. Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1\u2005L non-small cell lung cancer (NSCLC). Ann Oncol 2019; 30: Suppl. 5, V919\u2013V920. doi:10.1093\/annonc\/mdz394.081","DOI":"10.1093\/annonc\/mdz394.081"},{"key":"2024102403573011000_30.162.200387.58","unstructured":"AstraZeneca. Update on the Phase III NEPTUNE trial of Imfinzi plus tremelimumab in Stage IV non-small cell lung cancer. www.astrazeneca.com\/media-centre\/press-releases\/2019\/update-on-the-phase-iii-neptune-trial-of-imfinzi-plus-tremelimumab-in-stage-iv-non-small-cell-lung-cancer-21082019.html Date last updated: 21 August 2019."},{"key":"2024102403573011000_30.162.200387.59","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1053\/j.seminoncol.2019.10.002","article-title":"Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors","volume":"46","author":"Hopkins","year":"2019","journal-title":"Semin Oncol"},{"key":"2024102403573011000_30.162.200387.60","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0099"},{"key":"2024102403573011000_30.162.200387.61","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/annonc\/mdz453.001","article-title":"LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in KEYNOTE-042","volume":"30","author":"Herbst","year":"2019","journal-title":"Ann Oncol"},{"key":"2024102403573011000_30.162.200387.62","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz077"},{"issue":"Suppl 15.","key":"2024102403573011000_30.162.200387.63","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2019.37.15_suppl.102","article-title":"Association of STK11\/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer","volume":"37","author":"Skoulidis","year":"2019","journal-title":"J Clin Oncol"},{"key":"2024102403573011000_30.162.200387.64","doi-asserted-by":"crossref","unstructured":"Cho BJ , Lopes G , Kowalski DM, et al. Relationship between STK11 and KEAP1 mutational status and efficacy in KEYNOTE 04: pembrolizumab monotherapy versus platinum\u2014based chemotherapy as first-line therapy for PD-L1 positive advanced NSCLC. 2020 American Association for Cancer Research virtual Annual Meeting; April 27\u201328, 2020 Abstract CT084.","DOI":"10.1158\/1538-7445.AM2020-CT084"},{"key":"2024102403573011000_30.162.200387.65","doi-asserted-by":"crossref","first-page":"S817","DOI":"10.1016\/j.annonc.2020.08.1579","article-title":"IMpower150: a post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations","volume":"31","author":"West","year":"2020","journal-title":"Ann Oncol"},{"key":"2024102403573011000_30.162.200387.66","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.1016\/j.jtho.2019.08.428","article-title":"Mutations associated with sensitivity or resistance to immunotherapy in mNSCLC: analysis from the MYSTIC trial","volume":"14","author":"Rizvi","year":"2019","journal-title":"J Thoracic Oncol"},{"key":"2024102403573011000_30.162.200387.67","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds213"},{"key":"2024102403573011000_30.162.200387.68","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2010.0099"},{"key":"2024102403573011000_30.162.200387.69","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1200\/JCO.1997.15.8.2866","article-title":"Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival","volume":"15","author":"Graus","year":"1997","journal-title":"J Clin Oncol"},{"key":"2024102403573011000_30.162.200387.70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.03.028"},{"key":"2024102403573011000_30.162.200387.71","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13000-018-0712-1","article-title":"Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors","volume":"13","author":"Wang","year":"2018","journal-title":"Diagn Pathology"},{"key":"2024102403573011000_30.162.200387.72","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1007\/s12253-020-00832-0","article-title":"PD-L1 expression in small cell and large cell neuroendocrine carcinomas of lung: an immunohistochemical study with review of literature","volume":"26","author":"Guleria","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"2024102403573011000_30.162.200387.73","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jtho.2018.01.008","article-title":"Association of PD-L1 expression with tumor-infiltrating immune cells and mutation burden in high-grade neuroendocrine carcinoma of the lung","volume":"13","author":"Kim","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2024102403573011000_30.162.200387.74","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.lungcan.2017.03.006","article-title":"PD-L1 expression in neuroendocrine tumors of the lung","volume":"108","author":"Tsuruoka","year":"2017","journal-title":"Lung Cancer"},{"key":"2024102403573011000_30.162.200387.75","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03099-x"},{"key":"2024102403573011000_30.162.200387.76","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/JTO.0000000000000414","article-title":"Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer","volume":"10","author":"Ishii","year":"2015","journal-title":"J Thorac Oncol"},{"key":"2024102403573011000_30.162.200387.77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.06.023"},{"key":"2024102403573011000_30.162.200387.78","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0540-1"},{"key":"2024102403573011000_30.162.200387.79","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jtho.2016.09.002","article-title":"PD-L1 expression by two complementary diagnostic assays and mRNA in situ hybridisation in small cell lung cancer","volume":"12","author":"Yu","year":"2017","journal-title":"J Thoracic Oncol"},{"key":"2024102403573011000_30.162.200387.80","doi-asserted-by":"publisher","DOI":"10.1038\/nature12477"},{"key":"2024102403573011000_30.162.200387.81","doi-asserted-by":"publisher","DOI":"10.1038\/nature14664"},{"key":"2024102403573011000_30.162.200387.82","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00793"},{"key":"2024102403573011000_30.162.200387.83","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated pverall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133) I","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Suppl 15.","key":"2024102403573011000_30.162.200387.84","first-page":"9000","article-title":"Randomised phase II clinical trial of cisplatin\/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161","volume":"38","author":"Leal","year":"2020","journal-title":"J Oncol"},{"key":"2024102403573011000_30.162.200387.85","doi-asserted-by":"crossref","first-page":"ii77","DOI":"10.1093\/annonc\/mdz094","article-title":"Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1\u2005L) platinum-based chemotherapy (chemo): Results from the double-blind, randomised phase III CheckMate 451 study","volume":"30","author":"Owonikoko","year":"2019","journal-title":"Ann Oncol"},{"key":"2024102403573011000_30.162.200387.86","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jtho.2018.05.002","article-title":"Phase II study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC)","volume":"13","author":"Gadgeel","year":"2018","journal-title":"J Thoracic Oncol"},{"key":"2024102403573011000_30.162.200387.87","doi-asserted-by":"crossref","first-page":"x43","DOI":"10.1093\/annonc\/mdy511.004","article-title":"Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331","volume":"29","author":"Reck","year":"2018","journal-title":"Ann Oncol"},{"key":"2024102403573011000_30.162.200387.88","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.jtho.2019.01.008","article-title":"A randomised non-comparative phase II study of anti-programmed cell death-ligand 1 atezolizumab or chemotherapy as second-line therapy in patients with small cell lung cancer: results from the IFCT-1603 trial","volume":"14","author":"Pujol","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2024102403573011000_30.162.200387.89","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.cllc.2020.05.008","article-title":"Clinical activity and safety of atezolizumab in a phase 1 study of patients with relapsed\/refractory small-cell lung cancer","volume":"21","author":"Chiang","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"2024102403573011000_30.162.200387.90","first-page":"618","article-title":"Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158","volume":"15","author":"Chung","year":"2018","journal-title":"J Clin Oncol"},{"key":"2024102403573011000_30.162.200387.91","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.5069"},{"key":"2024102403573011000_30.162.200387.92","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.04.001"},{"key":"2024102403573011000_30.162.200387.93","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jtho.2019.10.004","article-title":"Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomised cohort","volume":"15","author":"Ready","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2024102403573011000_30.162.200387.94","doi-asserted-by":"crossref","first-page":"viii596","DOI":"10.1093\/annonc\/mdy298.001","article-title":"Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory\/resistant ED-SCLC from arm A of the phase II BALTIC study","volume":"29","author":"Bondarenko","year":"2018","journal-title":"Ann Oncol"},{"key":"2024102403573011000_30.162.200387.95","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.12.109"},{"key":"2024102403573011000_30.162.200387.96","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jtho.2018.10.003","article-title":"Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032","volume":"14","author":"Ready","year":"2019","journal-title":"J Thoracic Oncol"},{"key":"2024102403573011000_30.162.200387.97","doi-asserted-by":"crossref","first-page":"S1564","DOI":"10.21037\/jtd.2018.01.131","article-title":"Do immune checkpoint inhibitors need new studies methodology?","volume":"10","author":"Ferrara","year":"2018","journal-title":"J Thorac Dis"},{"key":"2024102403573011000_30.162.200387.98","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30098-5"},{"key":"2024102403573011000_30.162.200387.99","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0572-6"},{"key":"2024102403573011000_30.162.200387.100","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3520"},{"key":"2024102403573011000_30.162.200387.101","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70381-4"},{"key":"2024102403573011000_30.162.200387.102","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study","volume":"3","author":"Calabr\u00f2","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2024102403573011000_30.162.200387.103","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"key":"2024102403573011000_30.162.200387.104","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9\u201315) PROMISE-meso trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann Oncol"},{"key":"2024102403573011000_30.162.200387.105","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S1470-2045(20)30462-9","article-title":"Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in","volume":"21","author":"Nowak","year":"2020","journal-title":"Lancet Oncol"},{"key":"2024102403573011000_30.162.200387.106","doi-asserted-by":"crossref","unstructured":"Forde PM , Sun Z , Anagnostou V , et al. PrE0505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM) \u2013 A PrECOG LLC study. J Clin Oncol 2021; 38: Suppl. 15, 9003\u20139003. doi:10.1200\/JCO.2020.38.15_suppl.9003","DOI":"10.1200\/JCO.2020.38.15_suppl.9003"},{"key":"2024102403573011000_30.162.200387.107","doi-asserted-by":"crossref","unstructured":"Cedr\u00e9s S , Ponce-Aix S , Zugazagoitia J , et al. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS ONE 2015; 10: e0121071. doi:10.1371\/journal.pone.0121071","DOI":"10.1371\/journal.pone.0121071"},{"key":"2024102403573011000_30.162.200387.108","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2016.01.010","article-title":"Immune biomarkers PD-1\/PD-L1 and TLR3 in malignant pleural mesotheliomas","volume":"52","author":"Combaz-Lair","year":"2016","journal-title":"Hum Pathol"},{"key":"2024102403573011000_30.162.200387.109","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1016\/j.cllc.2019.04.010","article-title":"Shorter survival in malignant pleural mesothelioma patients with high PD-L1 expression associated with sarcomatoid or biphasic histology subtype: a series of 214 Cases From the Bio-MAPS Cohort","volume":"20","author":"Brosseau","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"2024102403573011000_30.162.200387.110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2017.04.032","article-title":"Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma","volume":"71","author":"Inaguma","year":"2018","journal-title":"Hum Pathol"},{"key":"2024102403573011000_30.162.200387.111","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jtho.2017.02.013","article-title":"The Immune microenvironment, genome-wide copy number aberrations, and survival in mesothelioma","volume":"12","author":"Thapa","year":"2017","journal-title":"J Thorac Oncol"},{"key":"2024102403573011000_30.162.200387.112","first-page":"1157","article-title":"Role of evaluating tumor-infiltrating lymphocytes, programmed death-1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma","volume":"55","author":"Losi","year":"2019","journal-title":"Int J Oncol"},{"key":"2024102403573011000_30.162.200387.113","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.269"},{"key":"2024102403573011000_30.162.200387.114","doi-asserted-by":"crossref","first-page":"e1009285","DOI":"10.1080\/2162402X.2015.1009285","article-title":"The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers","volume":"4","author":"Ujiie","year":"2015","journal-title":"Oncoimmunology"},{"key":"2024102403573011000_30.162.200387.115","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1093\/annonc\/mdy086","article-title":"Malignant pleural mesothelioma immune microenvironment and checkpoint expression: Correlation with clinical-pathological features and intratumor heterogeneity over time","volume":"29","author":"Pasello","year":"2018","journal-title":"Ann Oncol"},{"key":"2024102403573011000_30.162.200387.116","doi-asserted-by":"crossref","first-page":"639","DOI":"10.21037\/tlcr-19-485","article-title":"Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma","volume":"9","author":"Brockwell","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"2024102403573011000_30.162.200387.117","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2019.02.005","article-title":"High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes","volume":"130","author":"Ahmadzada","year":"2019","journal-title":"Lung Cancer"},{"key":"2024102403573011000_30.162.200387.118","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0171"},{"key":"2024102403573011000_30.162.200387.119","doi-asserted-by":"crossref","first-page":"e1638211","DOI":"10.1080\/2162402X.2019.1638211","article-title":"Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes","volume":"8","author":"Klampatsa","year":"2019","journal-title":"OncoImmunology"},{"key":"2024102403573011000_30.162.200387.120","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0804"},{"key":"2024102403573011000_30.162.200387.121","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ebiom.2019.09.003","article-title":"Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions","volume":"48","author":"Alcala","year":"2019","journal-title":"EBioMed"},{"key":"2024102403573011000_30.162.200387.122","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-1008"},{"key":"2024102403573011000_30.162.200387.123","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000471"},{"key":"2024102403573011000_30.162.200387.124","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1612074113"},{"key":"2024102403573011000_30.162.200387.125","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0620-3"},{"key":"2024102403573011000_30.162.200387.126","doi-asserted-by":"crossref","first-page":"S339","DOI":"10.1016\/j.jtho.2018.08.277","article-title":"Phase II trial of pembrolizumab (NCT02399371) in previously-treated malignant mesothelioma (MM): final analysis","volume":"13","author":"Desai","year":"2018","journal-title":"J Thoracic Oncol"},{"key":"2024102403573011000_30.162.200387.127","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0103"},{"key":"2024102403573011000_30.162.200387.128","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/j.jtho.2020.08.004","article-title":"First-line nivolumab+opilimumab","volume":"15","author":"Baas","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2024102403573011000_30.162.200387.129","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"Calabr\u00f2","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2024102403573011000_30.162.200387.130","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma","volume":"13","author":"Quispel-Janssen","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2024102403573011000_30.162.200387.131","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"2024102403573011000_30.162.200387.132","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Hassan","year":"2019","journal-title":"JAMA Oncol"},{"key":"2024102403573011000_30.162.200387.133","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2024102403573011000_30.162.200387.134","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30765-4"},{"key":"2024102403573011000_30.162.200387.135","doi-asserted-by":"crossref","first-page":"v747","DOI":"10.1093\/annonc\/mdz266","article-title":"Second\/third-line nivolumab","volume":"30","author":"Zalcman","year":"2019","journal-title":"Ann Oncol"},{"key":"2024102403573011000_30.162.200387.136","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.21037\/tlcr-19-686","article-title":"Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program","volume":"9","author":"Cantini","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"2024102403573011000_30.162.200387.137","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv277"},{"key":"2024102403573011000_30.162.200387.138","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/modpathol.2017.6","article-title":"Expression of PD-1 and PD-L1 in thymic epithelial neoplasms","volume":"30","author":"Weissferdt","year":"2017","journal-title":"Mod Pathol"},{"key":"2024102403573011000_30.162.200387.139","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000429"},{"key":"2024102403573011000_30.162.200387.140","doi-asserted-by":"crossref","first-page":"e0182665","DOI":"10.1371\/journal.pone.0182665","article-title":"Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors","volume":"12","author":"Arbour","year":"2017","journal-title":"PloS One"},{"key":"2024102403573011000_30.162.200387.141","doi-asserted-by":"crossref","first-page":"6993","DOI":"10.18632\/oncotarget.24075","article-title":"A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma","volume":"9","author":"Sakane","year":"2018","journal-title":"Oncotarget"},{"key":"2024102403573011000_30.162.200387.142","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"key":"2024102403573011000_30.162.200387.143","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho","year":"2019","journal-title":"J Clin Oncol"},{"key":"2024102403573011000_30.162.200387.144","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1470-2045(17)30239-5","article-title":"Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial","volume":"18","author":"Heery","year":"2017","journal-title":"Lancet Oncol"},{"key":"2024102403573011000_30.162.200387.145","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2019.03.012","article-title":"Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study","volume":"113","author":"Katsuya","year":"2019","journal-title":"Eur J Cancer"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0387-2020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:04:26Z","timestamp":1740373466000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0387-2020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,5]]},"references-count":145,"journal-issue":{"issue":"162","published-online":{"date-parts":[[2021,10,5]]},"published-print":{"date-parts":[[2021,12,31]]}},"alternative-id":["10.1183\/16000617.0387-2020"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0387-2020","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,5]]}}}